Special Issue

Mass Spectrometry-Based Metabolomics for Advancing Personalized Medicine

Message from the Guest Editors

This Special Issue of *Metabolites* is focused on mass-spectrometry-based metabolomics in the context of personalized medicine, and investigators are invited to present their relevant research results. This Special Issue aims to focus on relevant advancements using mass spectrometry tools for metabolomic research, with a focus on personalized medicine. These topics may include biomarker discovery and validation for diagnosis and disease stratification, together with methodological advancements and integration with other "omics" technologies to better understand metabolic pathway alterations.

Guest Editors

Prof. Dr. Cristina Adela luga


Department of Personalized Medicine and Rare Diseases, Institute of Biomedical Research—MedFuture, "Iuliu Haţieganu" University of Medicine and Pharmacy Cluj-Napoca, 400012 Cluj-Napoca, Romania

Dr. Radu-Cristian Moldovan

Department of Personalized Medicine and Rare Diseases, Institute of Biomedical Research—MedFuture, "Iuliu Haţieganu" University of Medicine and Pharmacy Cluj-Napoca, 400012 Cluj-Napoca, Romania

Deadline for manuscript submissions

30 April 2026



an Open Access Journal by MDPI

Impact Factor 3.7 CiteScore 6.9 Indexed in PubMed



mdpi.com/si/233554

Metabolites
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
metabolites@mdpi.com

mdpi.com/journal/metabolites





Metabolites

an Open Access Journal by MDPI

Impact Factor 3.7 CiteScore 6.9 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

The metabolome is the result of the combined effects of genetic and environmental influences on metabolic processes. Metabolomic studies can provide a global view of metabolism and thereby improve our understanding of the underlying biology. Advances in metabolomic technologies have shown utility for elucidating mechanisms which underlie fundamental biological processes including disease pathology. *Metabolites* is proud to be part of the development of metabolomics and we look forward to working with many of you to publish high quality metabolomic studies.

Editor-in-Chief

Dr. Amedeo Lonardo

Internal Medicine, Ospedale Civile di Baggiovara, Azienda Ospedaliero-Universitaria, 41126 Modena, Italy

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Biochemistry and Molecular Biology) / CiteScore - Q2 (Endocrinology, Diabetes and Metabolism)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.4 days after submission; acceptance to publication is undertaken in 3.6 days (median values for papers published in this journal in the first half of 2025).

